-
1.发明授权Method for treatment of bacterial infections with once or twice-weekly administered rifalazil 失效用一周或两周施用的里法拉唑治疗细菌感染的方法公开(公告)号：US07772228B2
公开(公告)日：2010-08-10
申请号：US10243141
申请日：2002-09-14
IPC分类号： A61K31/395
CPC分类号： A61K31/538 , A61K31/00 , A61K31/70 , C10M101/025 , C10M103/06 , C10M105/14 , C10M105/24 , C10M107/34 , C10M107/36 , C10M111/00 , C10M2201/0603 , C10M2201/0613 , C10M2201/0623 , C10M2201/0653 , C10M2201/0663 , C10M2201/0803 , C10M2201/0853 , C10M2201/0863 , C10M2201/0873 , C10M2201/1006 , C10M2201/1023 , C10M2201/1033 , C10M2201/1053 , C10M2201/123 , C10M2205/143 , C10M2205/163 , C10M2205/173 , C10M2205/183 , C10M2207/0225 , C10M2207/1203 , C10M2207/1213 , C10M2207/1253 , C10M2207/163 , C10M2207/183 , C10M2207/203 , C10M2207/243 , C10M2209/1033 , C10M2209/1045 , C10M2209/1055 , C10M2209/1065 , C10M2209/1075 , C10M2209/1085 , C10M2209/1095 , C10M2209/123 , Y10S514/924 , Y10S514/931 , A61K2300/00
摘要： A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
摘要翻译： 一种每周一次或每周两次给予利福拉齐治疗细菌感染的方法。 一种治疗由结核分枝杆菌引起的结核病，由分枝杆菌复合体引起的感染，肺炎衣原体引起的感染和幽门螺杆菌感染引起的感染的方法，通过对患有细菌感染的患者施用1-100mg的利福拉齐，每周一次或两次 。 在这种剂量方案中，治疗是快速，有效的，并且消除了每日剂量的1-50mg利福肼的不期望的继发症状。
-
2.发明授权Method for treatment of bacterial infections with once or twice-weekly administered rifalazil 有权用一周或两周施用的里法拉唑治疗细菌感染的方法公开(公告)号：US06316433B1
公开(公告)日：2001-11-13
申请号：US09464353
申请日：1999-12-15
IPC分类号： A61K3133
CPC分类号： A61K31/538 , A61K31/00 , A61K31/70 , C10M101/025 , C10M103/06 , C10M105/14 , C10M105/24 , C10M107/34 , C10M107/36 , C10M111/00 , C10M2201/0603 , C10M2201/0613 , C10M2201/0623 , C10M2201/0653 , C10M2201/0663 , C10M2201/0803 , C10M2201/0853 , C10M2201/0863 , C10M2201/0873 , C10M2201/1006 , C10M2201/1023 , C10M2201/1033 , C10M2201/1053 , C10M2201/123 , C10M2205/143 , C10M2205/163 , C10M2205/173 , C10M2205/183 , C10M2207/0225 , C10M2207/1203 , C10M2207/1213 , C10M2207/1253 , C10M2207/163 , C10M2207/183 , C10M2207/203 , C10M2207/243 , C10M2209/1033 , C10M2209/1045 , C10M2209/1055 , C10M2209/1065 , C10M2209/1075 , C10M2209/1085 , C10M2209/1095 , C10M2209/123 , Y10S514/924 , Y10S514/931 , A61K2300/00
摘要： A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
摘要翻译： 一种每周或每周两次施用利福拉齐治疗细菌感染的方法。 一种治疗由结核分枝杆菌引起的结核病，由分枝杆菌复合体引起的感染，肺炎衣原体引起的感染和幽门螺杆菌感染引起的感染的方法，通过对患有细菌感染的患者施用1-100mg的利福拉齐，每周一次或两次 。 在这种剂量方案中，治疗是快速，有效的，并且消除了每日剂量的1-50mg利福肼的不期望的继发症状。
-
3.发明授权Method for treatment of bacterial infections with once or twice-weekly administered rifalazil 失效用一周或两周施用的里法拉唑治疗细菌感染的方法公开(公告)号：US06566354B1
公开(公告)日：2003-05-20
申请号：US09972320
申请日：2001-10-05
IPC分类号： A61K3133
CPC分类号： A61K31/538 , A61K31/00 , A61K31/70 , C10M101/025 , C10M103/06 , C10M105/14 , C10M105/24 , C10M107/34 , C10M107/36 , C10M111/00 , C10M2201/0603 , C10M2201/0613 , C10M2201/0623 , C10M2201/0653 , C10M2201/0663 , C10M2201/0803 , C10M2201/0853 , C10M2201/0863 , C10M2201/0873 , C10M2201/1006 , C10M2201/1023 , C10M2201/1033 , C10M2201/1053 , C10M2201/123 , C10M2205/143 , C10M2205/163 , C10M2205/173 , C10M2205/183 , C10M2207/0225 , C10M2207/1203 , C10M2207/1213 , C10M2207/1253 , C10M2207/163 , C10M2207/183 , C10M2207/203 , C10M2207/243 , C10M2209/1033 , C10M2209/1045 , C10M2209/1055 , C10M2209/1065 , C10M2209/1075 , C10M2209/1085 , C10M2209/1095 , C10M2209/123 , Y10S514/924 , Y10S514/931 , A61K2300/00
摘要： A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
摘要翻译： 一种每周或每周两次施用利福拉齐治疗细菌感染的方法。 一种治疗由结核分枝杆菌引起的结核病，由分枝杆菌复合体引起的感染，肺炎衣原体引起的感染和幽门螺杆菌感染引起的感染的方法，通过对患有细菌感染的患者施用1-100mg的利福拉齐每周一次或两次 。 在这种剂量方案中，治疗是快速，有效的，并且消除了每日剂量的1-50mg利福肼的不期望的继发症状。
-
公开(公告)号：US4677061A
公开(公告)日：1987-06-30
申请号：US662878
申请日：1984-10-19
IPC分类号： G01N33/569 , C12Q1/06 , G01N33/566
CPC分类号： G01N33/56972 , Y10S435/968
摘要： Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associated with a change in status.
摘要翻译： 提供了用于确定多发性硬化症患者状态变化的方法和组合物。 特别地，确定具有与增殖相关的特异性表面标志物的辅助或抑制T细胞亚群的比例，其中特定比值与状态变化相关联。
-
5.发明授权Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis 失效抑制炎症过程和缓解与多发性硬化有关的症状的方法公开(公告)号：US06737059B1
公开(公告)日：2004-05-18
申请号：US08333947
申请日：1994-11-03
申请人： Lynn M. Rose
发明人： Lynn M. Rose
IPC分类号： A01K39395
CPC分类号： C07K16/2845 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2319/00
摘要： Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory disease processes associated with the multiple sclerosis disease, by adminstering to a patient a phamaceutically effective amount of mAb 23F2G or an antibody that competes with mAb 23F2G for binding to LFA-1.
摘要翻译： 公开了通过给予患者药物有效量的mAb 23F2G或与mAb竞争的抗体来减轻与炎性疾病状态相关的症状的方法，更具体地涉及抑制与多发性硬化症相关的炎性疾病过程 23F2G用于结合LFA-1。
-
6.发明授权Murine and humanizer 23F2G antibodies and cell lines expressing said antibodies 失效鼠和人源化23F2G抗体和表达所述抗体的细胞系
公开(公告)号：US5854070A
公开(公告)日：1998-12-29
申请号：US785571
申请日：1997-01-21
申请人： Lynn M. Rose
发明人： Lynn M. Rose
CPC分类号： C07K16/2845 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease, by administering a pharmaceutically effective amount of antibody substance immunologically reactive with the common .beta. chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1.
摘要翻译： 公开了减轻与炎性疾病状态相关的症状的方法，更具体地涉及抑制与多发性硬化疾病相关的炎性过程的方法，方法是通过施用药学上有效量的与常见β链（CD18）免疫反应的抗体物质 人白细胞整合素和/或与mAb 60.3竞争结合人LFA-1。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.022 秒)
